Roche is investing $ 50 billion in the US because the threat of tariffs on pharmaceuticals is delayed

Swiss pharmaceutical giant Rosh on Tuesday – Note The fact that it is $ 50 billion in the United States over the next five years, amid concern for the impact of possible new tariffs on the White House on pharmaceutical goods from the border.

Investments will create more than 12,000 jobs, Rosh said – 1000 with the company, and the rest supports new US production opportunities.

Formatically, the giant will introduce cash in the creation of new modern research and development sites (NDDKR), strengthening and expanding production facilities in Indiana, Pennsylvania, Massachusetts and California. The new NDKR site in Massachusetts will be used for II research and act as a center for cardiovascular, renal and metabolism.

The financing package will also be used to create a new 900,000 square feet production center in an unknown location to support the “extended weight loss portfolio”.

Once the new investment in the production potential is completed, Rosh said he would export more medicines from the US than imports.

Pharmaceutical companies seek to strengthen their presence in the US against the background intimidation From President Donald Trump to stop the release of the industry for imports.

“We’re going to announce very quickly the main tariff for pharmaceuticals,” he said earlier this month.

This developing story is updated.